Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors

AIM: The BRAF mutation is a rare pathogenetic alternative to KIT/PDGFRA mutation in GIST and causes Imatinib resistance. A recent description of KIT and BRAF mutations co-occurring in an untreated GIST has challenged the concept of their being mutually exclusive and may account for ab initio resista...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Oncotarget
Главные авторы: Rossi, Sabrina, Sbaraglia, Marta, Dell'Orto, Marta Campo, Gasparotto, Daniela, Cacciatore, Matilde, Boscato, Elena, Carraro, Valentina, Toffolatti, Luisa, Gallina, Giovanna, Niero, Monia, Pilozzi, Emanuela, Mandolesi, Alessandra, Sessa, Fausto, Sonzogni, Aurelio, Mancini, Cristina, Mazzoleni, Guido, Romeo, Salvatore, Maestro, Roberta, Dei Tos, Angelo P.
Формат: Artigo
Язык:Inglês
Опубликовано: Impact Journals LLC 2016
Предметы:
Research Paper: Pathology
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5058667/
https://ncbi.nlm.nih.gov/pubmed/27097112
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.8768
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы